TOLREMO therapeutics

TOLREMO therapeutics is a biopharmaceutical company that develops small molecule inhibitors targeting non-genetic cancer drug resistance pathways, specifically blocking transcriptional escape mechanisms that enable cancer cells to survive targeted therapies. The company's mission is to tackle non-oncogene addiction in cancer by blocking transcriptional escape pathways that operate parallel to the primary oncogene signaling axis. Leveraging a proprietary phenotypic screening platform, TOLREMO has uncovered a novel role for CBP/p300 as an epigenetic master regulator of transcriptional resistance. The company's lead clinical compound, TT125-802, is an orally available small molecule inhibitor of the bromodomain of CBP/p300 with a differentiated, best-in-class safety profile and activity as a single agent in solid tumors. TT125-802 blocks the transcription of genes involved in primary and acquired resistance to targeted treatment, representing a novel therapeutic approach to addressing a major challenge in cancer treatment. The clinical development plan focuses on prevention of resistance by combining TT125-802 with a range of targeted therapies, following rapid dose escalation as monotherapy, while also exploring the compound's monotherapy activity in non-small cell lung cancer. TOLREMO's strategy of targeting non-oncogene addiction represents a differentiated approach with significant therapeutic potential both as monotherapy and in combination with targeted therapies in solid tumors and hematological malignancies. The company's team brings expertise in medicinal chemistry, bioinformatics, and therapeutic development. Founded in 2017 and headquartered in Zurich, Switzerland, TOLREMO therapeutics has raised $55.8M in Series A funding from investors including BioMedPartners, Altos Ventures Management, Redalpine, Zurcher Kantonalbank, MK Venture Capital, HEMEX, Wille Finance, EIT Health, BaseLaunch, and InQbator.